Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Neuberg

Showing results (251-260 of 354) with videos related to

Pageof 36
Sort By:
Leukemia & Lymphoma|January 25, 2022
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adultsPhilip Amrein, Karen Ballen, Kristen Stevenson, et al.
Nature Medicine|August 12, 2020
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphomaFathima Zumla Cader, Xihao Hu, Walter L Goh, et al.
Leukemia & Lymphoma|March 15, 2022
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclaxEvan C Chen, Yiwen Liu, Courtney E Harris, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
British Journal of Haematology|June 13, 2009
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaJonathan W Friedberg, Jennifer L Kelly, Donna Neuberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma VaccinesJohn M Goldberg, David E Fisher, George D Demetri, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2018
Autochthonous tumors driven by <i>Rb1</i> loss have an ongoing requirement for the RBP2 histone demethylaseSamuel K McBrayer, Benjamin A Olenchock, Gabriel J DiNatale, et al.
Nature|March 25, 2011
DHODH modulates transcriptional elongation in the neural crest and melanomaRichard Mark White, Jennifer Cech, Sutheera Ratanasirintrawoot, et al.
The New England Journal of Medicine|June 22, 2017
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular DiseaseSiddhartha Jaiswal, Pradeep Natarajan, Alexander J Silver, et al.
Nature Cancer|December 23, 2021
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatmentCatherine Gutierrez, Aziz M Al'Khafaji, Eric Brenner, et al.
Pageof 36

Showing results (251-260 of 354) with videos related to

Sort By:
Pageof 36
Leukemia & Lymphoma|January 25, 2022
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adultsPhilip Amrein, Karen Ballen, Kristen Stevenson, et al.
Nature Medicine|August 12, 2020
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphomaFathima Zumla Cader, Xihao Hu, Walter L Goh, et al.
Leukemia & Lymphoma|March 15, 2022
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclaxEvan C Chen, Yiwen Liu, Courtney E Harris, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
British Journal of Haematology|June 13, 2009
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaJonathan W Friedberg, Jennifer L Kelly, Donna Neuberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma VaccinesJohn M Goldberg, David E Fisher, George D Demetri, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2018
Autochthonous tumors driven by <i>Rb1</i> loss have an ongoing requirement for the RBP2 histone demethylaseSamuel K McBrayer, Benjamin A Olenchock, Gabriel J DiNatale, et al.
Nature|March 25, 2011
DHODH modulates transcriptional elongation in the neural crest and melanomaRichard Mark White, Jennifer Cech, Sutheera Ratanasirintrawoot, et al.
The New England Journal of Medicine|June 22, 2017
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular DiseaseSiddhartha Jaiswal, Pradeep Natarajan, Alexander J Silver, et al.
Nature Cancer|December 23, 2021
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatmentCatherine Gutierrez, Aziz M Al'Khafaji, Eric Brenner, et al.
Pageof 36